214 related articles for article (PubMed ID: 31489694)
1. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.
Deshayes S; Khellaf M; Zarour A; Layese R; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Cliquennois M; Ebbo M; Le Guenno G; Salles G; Bonmati C; Teillet F; Galicier L; Lambotte O; Hot A; Lefrère F; Mahévas M; Canoui-Poitrine F; Michel M; Godeau B
Am J Hematol; 2019 Dec; 94(12):1314-1324. PubMed ID: 31489694
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.
Khellaf M; Charles-Nelson A; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Ebbo M; Le Guenno G; Cliquennois M; Salles G; Bonmati C; Teillet F; Galicier L; Hot A; Lambotte O; Lefrère F; Sacko S; Kengue DK; Bierling P; Roudot-Thoraval F; Michel M; Godeau B
Blood; 2014 Nov; 124(22):3228-36. PubMed ID: 25293768
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study.
Mageau A; Bonnotte B; Ebbo M; Dossier A; Galicier L; Souchaud-Debouverie O; Orvain C; Gerfaud-Valentin M; Gobert D; Riviere E; Audia S; Mahevas M; Michel M; Viallard JF; Godeau B
Platelets; 2023 Dec; 34(1):2200848. PubMed ID: 37128870
[TBL] [Abstract][Full Text] [Related]
5. Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.
Hindilerden F; Yönal-Hindilerden İ; Yenerel MN; Nalçacı M; Diz-Küçükkaya R
Turk J Haematol; 2017 Mar; 34(1):72-80. PubMed ID: 27102929
[TBL] [Abstract][Full Text] [Related]
6. Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.
Reboursiere E; Fouques H; Maigne G; Johnson H; Chantepie S; Gac AC; Reman O; Macro M; Benabed K; Troussard X; Damaj G; Cheze S
Int J Hematol; 2016 Jul; 104(1):85-91. PubMed ID: 27040278
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study.
Tjønnfjord E; Holme PA; Darne B; Khelif A; Waage A; Michel M; Ben Romdhan N; Ghanima W
Br J Haematol; 2020 Nov; 191(3):460-465. PubMed ID: 32342497
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.
Oved JH; Lee CSY; Bussel JB
J Pediatr; 2017 Dec; 191():225-231. PubMed ID: 29173312
[TBL] [Abstract][Full Text] [Related]
9. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment.
Chang H; Tang TC; Hung YS; Li PL; Kuo MC; Wu JH; Wang PN
Eur J Haematol; 2018 Oct; 101(4):549-555. PubMed ID: 30007087
[TBL] [Abstract][Full Text] [Related]
10. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P
Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab.
Bhatt V; Shune L; Lauer E; Lubin M; Devlin SM; Scaradavou A; Parameswaran R; Perales MA; Ponce DM; Mantha S; Kernan NA; Barker JN
Bone Marrow Transplant; 2016 Dec; 51(12):1579-1583. PubMed ID: 27643868
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
13. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
[TBL] [Abstract][Full Text] [Related]
15. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
[TBL] [Abstract][Full Text] [Related]
16. [Treatment outcome of immune thrombocytopenia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2012 Oct; 153(41):1613-21. PubMed ID: 23045311
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Deshayes S; Mahévas M; Godeau B
Rev Med Interne; 2021 Jan; 42(1):32-37. PubMed ID: 32680716
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial.
Mahévas M; Azzaoui I; Crickx E; Canoui-Poitrine F; Gobert D; Languille L; Limal N; Guillaud C; Croisille L; Jeljeli M; Batteux F; Baloul S; Fain O; Pirenne F; Weill JC; Reynaud CA; Godeau B; Michel M
Haematologica; 2021 Sep; 106(9):2449-2457. PubMed ID: 32817288
[TBL] [Abstract][Full Text] [Related]
19. Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect.
Moulis G; Lapeyre-Mestre M; Palmaro A; Sailler L
J Thromb Haemost; 2017 Apr; 15(4):785-791. PubMed ID: 28078756
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis.
Wang J; Li Y; Wang C; Zhang Y; Gao C; Lang H; Chen X
Biomed Res Int; 2018; 2018():1316096. PubMed ID: 30648105
[No Abstract] [Full Text] [Related]
[Next] [New Search]
